Mobile Lads Corp. (MOBO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 554.54 Thousand USD | -56.72% |
| 2021 | 1.28 Million USD | 29.21% |
| 2020 | 991.58 Thousand USD | -3.26% |
| 2019 | 1.02 Million USD | 0.0% |
| 2016 | 3.6 Million USD | 1148.65% |
| 2015 | 288.87 Thousand USD | 1079.09% |
| 2014 | 24.5 Thousand USD | 231.08% |
| 2013 | 7400.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 112.72 Thousand USD | -15.82% |
| 2023 Q2 | 110.13 Thousand USD | -2.3% |
| 2022 Q1 | 136.81 Thousand USD | 0.0% |
| 2022 FY | 554.54 Thousand USD | -56.72% |
| 2022 Q4 | 133.91 Thousand USD | -19.01% |
| 2022 Q3 | 165.34 Thousand USD | 226.83% |
| 2022 Q2 | 50.58 Thousand USD | -63.02% |
| 2021 FY | 1.28 Million USD | 29.21% |
| 2020 FY | 991.58 Thousand USD | -3.26% |
| 2019 FY | 1.02 Million USD | 0.0% |
| 2017 Q1 | 642.09 Thousand USD | 22.7% |
| 2016 Q4 | 523.28 Thousand USD | -76.27% |
| 2016 Q2 | 836 Thousand USD | 1858.41% |
| 2016 Q3 | 2.2 Million USD | 163.77% |
| 2016 Q1 | 42.68 Thousand USD | 17.54% |
| 2016 FY | 3.6 Million USD | 1148.65% |
| 2015 FY | 288.87 Thousand USD | 1079.09% |
| 2015 Q4 | 36.31 Thousand USD | -26.79% |
| 2015 Q3 | 49.6 Thousand USD | -51.82% |
| 2015 Q2 | 102.95 Thousand USD | 691.11% |
| 2015 Q1 | 13.01 Thousand USD | 525.97% |
| 2014 FY | 24.5 Thousand USD | 231.08% |
| 2014 Q1 | 2500.00 USD | 0.0% |
| 2014 Q2 | 1667.00 USD | -33.32% |
| 2014 Q4 | 2079.00 USD | -88.61% |
| 2014 Q3 | 18.25 Thousand USD | 995.02% |
| 2013 FY | 7400.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 58.474% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 89.002% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 98.124% |
| Nascent Biotech, Inc. | 2.22 Million USD | 75.131% |
| Rebus Holdings, Inc. | 664 Thousand USD | 16.484% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.512% |
| Qrons Inc. | 643.67 Thousand USD | 13.847% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -42.35% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.035% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -33.471% |
| Skye Bioscience, Inc. | 13.54 Million USD | 95.907% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.361% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 88.724% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -111.88% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.352% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 80.984% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 63.077% |
| Mesoblast Limited | 5.9 Million USD | 90.604% |
| Marizyme, Inc. | 19.23 Million USD | 97.118% |
| Genus plc | 147.7 Million USD | 99.625% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 93.683% |
| Pharming Group N.V. | 225.49 Million USD | 99.754% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 72.932% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 58.664% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 93.35% |
| ContraFect Corporation | 56.88 Million USD | 99.025% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 87.421% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 62.499% |
| IMV Inc. | 37.7 Million USD | 98.529% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 80.126% |
| MultiCell Technologies, Inc. | 567.42 USD | -97631.134% |
| ONE Bio Corp. | 6.44 Million USD | 91.394% |
| Accustem Sciences Inc. | 3.74 Million USD | 85.198% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.355% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -4.245% |
| Q BioMed Inc. | 3.43 Million USD | 83.864% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.756% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 78.895% |
| Biomind Labs Inc. | 994.18 Thousand USD | 44.221% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.442% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 68.486% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 91.745% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 70.256% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2318.184% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 96.536% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 69.781% |
| GB Sciences, Inc. | 1.42 Million USD | 60.961% |
| Alpha Cognition Inc. | 9.7 Million USD | 94.286% |
| HST Global, Inc. | 140.9 Thousand USD | -293.555% |
| CSL Limited | 3.44 Billion USD | 99.984% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 50.703% |
| Halberd Corporation | 74.84 Thousand USD | -640.956% |
| Enzolytics Inc. | 2.17 Million USD | 74.556% |
| Agentix Corp. | 1.37 Million USD | 59.574% |
| Resverlogix Corp. | 12.71 Million USD | 95.638% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 84.81% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.964% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 46.883% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 76.941% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 64.888% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 83.714% |
| AVAX Technologies, Inc. | 7.31 Million USD | 92.414% |
| Zenith Capital Corp. | 8.94 Million USD | 93.799% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.933% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -3083.204% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 77.414% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -223.333% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 71.131% |
| Kadimastem Ltd | 2.41 Million USD | 76.991% |
| Helix BioMedix, Inc. | 1.97 Million USD | 71.879% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 94.897% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.586% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -205.56% |
| LadRx Corporation | 3.81 Million USD | 85.452% |
| Cell Source, Inc. | 4.32 Million USD | 87.179% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 39.952% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 39.952% |
| NovAccess Global Inc. | 2.46 Million USD | 77.519% |
| Affymax, Inc. | 39.38 Million USD | 98.592% |
| Itoco Inc. | 919.14 Thousand USD | 39.667% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 86.916% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 50.443% |
| CytoDyn Inc. | 18.05 Million USD | 96.929% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2103.29% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -151.977% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 60.942% |
| SYBLEU INC | 160.87 Thousand USD | -244.704% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 69.469% |
| International Stem Cell Corporation | 5.27 Million USD | 89.479% |
| Bioxytran, Inc. | 3.82 Million USD | 85.484% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -953.429% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -2625.979% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.471% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 65.726% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 24.637% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 82.175% |
| Neutra Corp. | 243.82 Thousand USD | -127.44% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 96.823% |
| PureTech Health plc | 144.59 Million USD | 99.616% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 97.294% |
| IXICO plc | 4.7 Million USD | 88.219% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 93.696% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.529% |
| CSL Limited | 3.89 Billion USD | 99.986% |
| Cellectis S.A. | 97.32 Million USD | 99.43% |